%0 Journal Article
%A Salvador-Martin, Sara
%A Kaczmarczyk, Bartosz
%A Alvarez, Rebeca
%A Navas-Lopez, Victor Manuel
%A Gallego-Fernandez, Carmen
%A Moreno-Alvarez, Ana
%A Solar-Boga, Alfonso
%A Sanchez, Cesar
%A Tolin, Mar
%A Velasco, Marta
%A Muñoz-Codoceo, Rosana
%A Rodriguez-Martinez, Alejandro
%A Vayo, Concepcion A
%A Bossacoma, Ferran
%A Pujol-Muncunill, Gemma
%A Fobelo, Maria J
%A Millan-Jimenez, Antonio
%A Magallares, Lorena
%A Martinez-Ojinaga, Eva
%A Loverdos, Ines
%A Eizaguirre, Francisco J
%A Blanca-Garcia, Jose A
%A Clemente, Susana
%A Garcia-Romero, Ruth
%A Merino-Bohorquez, Vicente
%A Gonzalez-de-Caldas, Rafael
%A Vazquez, Enrique
%A Dopazo, Ana
%A Sanjurjo-Saez, Maria
%A Lopez-Fernandez, Luis A
%T Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
%D 2021
%@ 1999-4923
%U http://hdl.handle.net/10668/16953
%X Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged  Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or 0.6 or  Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.
%K Crohn disease
%K Adalimumab
%K Biomarker
%K Gene expression
%K Inflammatory bowel disease
%K Infliximab
%K Ulcerative colitis
%K Área de Gestión Sanitaria Sur de Sevilla
%~